5-SENSE Score Validation Study

Enrolling by invitationOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Epilepsy Intractable
Interventions
OTHER

Stereoelectroencephalography (SEEG)

Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.

Trial Locations (19)

3800

Monash University, Melbourne

5020

Christian Doppler University Hospital Paracelsus Medical University Salzburg and Centre for Cognitive Neuroscience Salzburg, Salzburg

8200

Danish Epilepsy Centre, Aarhus Universitets Hospital, Aarhus

15232

Presbyterian-Shadyside Hospital, Pittsburgh

27710

Duke University Health System, Durham

32610

University of Florida College of Medicine, Gainesville

60611

Northwestern University, Chicago

Unknown

Mater Health, Brisbane

Alfred Health, Melbourne

Dalhousie Universiry and Hospital, Dalhousie

Wester University, London

Departmet of Neurology, Masaryk University Brno, Brno

Grenoble Institute of Neurosciences, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble

Epilepsy Department University Hospitals of Marseille, Marseille

Epilepsy Centre, University Hospital Freiburg, Freiburg im Breisgau

"Carol Davila University of Medicine and Pharmacy", Bucharest

Hospital Universitario y Politecnico La Fe, Valencia

Department of Clinical Neurosciences chez CHUV; Centre Hospitalier Universitaire Vaudois, Lausanne

606-8303

University School of Medicine Kyoto, Kyoto

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Christian Doppler University Hospital

UNKNOWN

lead

Duke University

OTHER

NCT06138808 - 5-SENSE Score Validation Study | Biotech Hunter | Biotech Hunter